ClinicalTrials.gg
CompletedNCT02187562Updated Jul 14, 2014

Effect of Steady State Meloxicam on Low Dose Aspirin Induced Inhibition of Platelet Aggregation and Thromboxane Synthesis in Healthy Males and Females

A Phase 1 interventional study of Meloxicam and Aspirin in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-14.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The objective of this study was to investigate the influence of meloxicam on low dose aspirin induced inhibition of platelet aggregation and thromboxane B2, when meloxicam is given before aspirin.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female subjects as determined by results of screening
  • Signed written in accordance with Good Clinical Practice (GCP) and local legislation
  • Age >=18 and \<= 60 years
  • The (BMI) ≥ 18.5 kg/m2 (square meters) and ≤ 29.9 kg/m2.
  • Laboratory values within a clinical normal range

Exclusion criteria

Exclusion Criteria:

  • Any finding of the medical examination (including blood pressure, pulse rate and (ECG)) deviating from normal and of clinical relevance
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Surgery of the gastro-intestinal tract (except appendectomy)
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  • History of orthostatic hypotension, fainting spells or blackouts
  • Chronic or relevant acute infections
  • History of allergy/ (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  • Intake of drugs with a long half-life (> 24 hours) (\< 1 month prior to administration or during the trial)
  • Use of any drugs, which might influence the results of the trial, in particular aspirin containing drugs(\< 14 days prior to administration or during the trial)
  • Participation in another trial with an drug (\< 1 months prior to administration (at least 10 times the relevant elimination half-life) or during trial)
  • Having had prescription medication 2 weeks prior to study drug administration or over the counter medication 1 week prior to study drug administration (at least 10 times the relevant elimination half-life)
  • Smoker (> 10 cigarettes or 3 cigars or 3 pipes/day)
  • Inability to refrain from smoking on trial days
  • Alcohol abuse (> 60 grams (g)/day)
  • Drug abuse
  • Blood donation or loss > 400 mL (\< 1 month prior to administration or during the trial)
  • Excessive physical activities (\< 5 days prior to administration or during the trial)
  • Any ECG value outside of the reference range of clinical relevance including, but not limited to > 480 ms or QRS interval > 110 ms
  • History of any familial bleeding disorder
  • History of haemorrhagic diatheses
  • History of gastrointestinal ulcer, perforation or bleeding
  • History of bronchial asthma
  • Inability to comply with dietary regimen of study centre
  • Inability to comply with investigator's instructions

For female subjects:

  • Pregnancy
  • Positive pregnancy test
  • No adequate (e.g. sterilisation, intrauterine device (IUP), oral contraceptives)
  • Inability to maintain this adequate contraception during the whole study period
  • Lactation period

Ovarian hormone substitution and oral contraception have to be continued during the study

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Meloxicam/Aspirin

    Meloxicam days 1-10 / Aspirin days 5-10

    Drug: Meloxicam · Drug: Aspirin

  • Active comparator
    Aspirin

    Aspirin 2 days

    Drug: Aspirin

Interventions

06

What researchers measure

Primary outcomes

  1. Arachidonic acid induced platelet aggregation

    Time frame: up to day 11 (treatment 1), up to day 3 (treatment 2)

Secondary outcomes

  1. Collagen-induced Platelet Aggregation

    Time frame: up to day 11 (treatment 1), up to day 3 (treatment 2)

  2. Adenosine diphosphate (ADP) Induced Platelet Aggregation

    Time frame: up to day 11 (treatment 1), up to day 3 (treatment 2)

  3. Serum Thromboxane B2 production

    Time frame: up to day 11 (treatment 1), up to day 3 (treatment 2)

  4. Number of patients with adverse events

    Time frame: up to 6 weeks

  5. Number of patients with abnormal changes in laboratory parameters

    Time frame: up to day 11 (treatment 1), up to day 3 (treatment 2)

  6. Number of patients with abnormal changes in 12-lead electrocardiogram (ECG)

    Time frame: Screening, 24 hours after the last Aspirin intake

  7. Number of patients with clinically significant changes in vital signs

    Time frame: Screening, 24 hours after the last Aspirin intake

  8. Assessment of tolerability on a 4-point scale

    Time frame: 24 hours after the last Aspirin intake

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2002 and a primary completion of Aug 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2014
First posted
Jul 11, 2014
Start
Jul 2002
Primary completionActual
Aug 2002
Last update
Jul 14, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02187562
Responsible party
Sponsor
First posted
Jul 11, 2014
Start date
Jul 2002
Primary completion
Aug 2002
Last update
Jul 14, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Meloxicam

Start the discussion